New PARP Inhibitor Approved for Ovarian Cancer
The FDA approved a molecularly targeted therapeutic for the maintenance treatment of patients with recurrent epithelial ovarian and other cancers.
Progress Against Cancer
The FDA approved a molecularly targeted therapeutic for the maintenance treatment of patients with recurrent epithelial ovarian and other cancers.
The FDA issued the first-ever approval of a treatment for patients with a rare, aggressive form of skin cancer called Merkel cell carcinoma.
The FDA expanded the use of the immunotherapeutic pembrolizumab to include the treatment of certain patients with Hodgkin lymphoma.
A molecularly targeted therapeutic was approved for use in combination with any aromatase inhibitor for the treatment of postmenopausal women with a certain form of breast cancer.
Study reports that cancer type and mortality differs among ethnic groups, suggesting a need for targeted public health efforts. A new study suggests that the growing Hispanic population in the United States may experience...
A study suggests that diet during adolescence and early adulthood may be associated with premenopausal breast cancer risk.
Study: Women who have a false-positive screening mammogram are more likely to delay their next breast cancer screening.
The FDA expanded the use of a targeted therapy for a form of non-Hodgkin lymphoma called marginal zone lymphoma.
An immune checkpoint inhibitor – a form of immunotherapy – has had its use expanded for use in the treatment of bladder cancer.
A study involving normal-weight postmenopausal women found that poor metabolic health was associated with an increased risk for colorectal cancer
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More